Medicxi
Finance · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
25 Great Pulteney St, London, Greater Lo...Phone Number
+44 2079521788Website
www.medicxi.comRevenue
$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
2
1
1
1
About Medicxi
Medicxi is a healthcare investment firm that specializes in supporting innovative biotechnology companies. They focus on early to mid-stage companies, providing financial resources and strategic guidance to advance their research and development efforts. The firm aims to enhance patient outcomes through its investments in cutting-edge therapeutic solutions. Their target clients include emerging biotech firms and healthcare innovators seeking capital and expertise to drive their projects forward.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Medicxi your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Medicxi, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Medicxi has recently received funding, and reach out quickly before it becomes old news!
Check out if Medicxi is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Medicxi recently announced quarterly report
Click to see if Medicxi had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Medicxi
Product Launch: Get notified when Medicxi launches new products
Funding: Get notified immidiatlly once Medicxi has new funding data
Recommended Actions
Find VP level buyers at Medicxi
Find more new buyers
Compare Similar Companies to Medicxi
Compare insights from companies similar to Medicxi, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Medicxi
$5M
11-50
Private
$579.8M
2016
N/A
Company Profile Activity
Activity Insights
Medicxi is experiencing very low activity levels compared to other companies in the Finance sector.
What does this means?
Medicxi is drawing exceptional interest within the Finance industry, suggesting notable developments or strong market momentum, learn more about Medicxi.
Medicxi financials insights
Gather financial insights about Medicxi, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Private Equity
$579.8M
Medicxi Tech Stack
A closer look at the technologies used by Medicxi
See more technologies
Most Recent Scoops
Project
Spending/Investment
Project
Spending/Investment
Funding
Funding
Project
Spending/Investment
Event
Events, Engineering, Research & Development, Training, Machine Learning, Learning & Development, Search, Laboratory Operations, Medical Education & Training, Medical Research, Chemical Engineering, Artificial Intelligence, Clinical Operations, Healthcare Technology, HR Operations, Operations
Medicxi News & Media
Medicxi Announces €500 Million Fund V
New fund will continue Medicxi's successful asset-centric company creation and investment strategy. LONDON, Nov. 14, 2025 /PRNewswire/ -- Medicxi, a leading European life sciences venture capital firm, today announced the closing of Medicxi V, a €500 million fund dedicated to building and...Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company KER-0193, a novel, orally bioavailable small molecule, was granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA Acquisition strengthens...Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company KER-0193, a novel, orally bioavailable small molecule, was granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA Acquisition strengthens...Vicebio, next-generation vaccine biotech, to be acquired by Sanofi for US$1.6 billion
Sanofi will gain access to Molecular Clamp technology that enables development of next-generation multivalent vaccines against respiratory pathogens and beyond Lead asset VXB-241 is a bivalent vaccine targeting Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV), currently...
Read more news
Top Finance Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Medicxi
Sign Up For FreeTo access detailed company insights
Medicxi is a healthcare investment firm that specializes in supporting innovative biotechnology companies. They focus on early to mid-stage companies, providing financial resources and strategic guidance to advance their research and development efforts. The firm aims to enhance patient outcomes through its investments in cutting-edge therapeutic s... Read More
